Trials / Recruiting
RecruitingNCT05773937
A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors
A Phase I Clinical Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of 9MW2821 in Advanced Malignant Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study is a Phase 1, first-in-human, open-label, dose-escalation and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, preliminary antitumor activity and immunogenicity of 9MW2821 administered by intravenous (IV) infusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 9MW2821 | All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15). |
Timeline
- Start date
- 2022-06-21
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2023-03-17
- Last updated
- 2024-09-19
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05773937. Inclusion in this directory is not an endorsement.